A phase II study of laquinimod in Crohn's disease

Conclusions
Laquinimod was safe and well tolerated, and the effects on remission and response of the 0.5 mg dose suggest a treatment benefit in patients with CD.

Trial registration number
NCT00737932.

Source: Gut - July 9, 2015 Category: Gastroenterology Authors: D'Haens, G., Sandborn, W. J., Colombel, J. F., Rutgeerts, P., Brown, K., Barkay, H., Sakov, A., Haviv, A., Feagan, B. G., on behalf of the Laquinimod for Crohn's Disease Investigators, on behalf of the Laquinimod for Crohn's Disease Investigators, Baert, Tags: Crohn's disease, Open access Inflammatory bowel disease Source Type: research